Skip to main content

CG Oncology, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

CGON$72.64-2.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · AdditionalPaid-in · Accumulated · TotalStockholders'
SharesAmountCapitalDeficitEquity
Balance as of December 31, 202476,154,783$8$951,350$(217,981)$733,377
Issuance of common stock66,506—682—682
Stock-based compensation expense——5,151—5,151
Net loss———(34,452)(34,452)
Balance as of March 31, 202576,221,289$8$957,183$(252,433)$704,758
Issuance of common stock10,570—19—19
Stock-based compensation expense——7,007—7,007
Net loss———(41,426)(41,426)
Balance as of June 30, 202576,231,859$8$964,209$(293,859)$670,358
Balance as of December 31, 202580,689,128$8$1,131,570$(378,976)$752,602
Issuance of common stock in connection with a public offering, net of issuance costs6,941,4071391,409—391,410
Issuance of common stock377,226—1,495—1,495
Stock-based compensation expense——6,474—6,474
Net loss———(60,202)(60,202)
Balance as of March 31, 202688,007,761$9$1,530,948$(439,178)$1,091,779
Issuance of common stock298,629—2,061—2,061
Stock-based compensation expense——14,334—14,334
Net loss———(79,056)(79,056)
Balance as of June 30, 202688,306,390$9$1,547,343$(518,234)$1,029,118
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.